Skip to content

Commit

Permalink
Update tests
Browse files Browse the repository at this point in the history
  • Loading branch information
@calvinlu3
calvinlu3 committed Apr 30, 2024
1 parent c92a745 commit 99cb699
Show file tree
Hide file tree
Showing 2 changed files with 23 additions and 23 deletions.
27 changes: 13 additions & 14 deletions core/src/test/resources/test_cancer_type_treatments.tsv
View file
Original file line number Diff line number Diff line change
Expand Up @@ -149,20 +149,19 @@ KRAS G12C AML
KRAS G12D AML
KRAS G12C Leukemia
KRAS G12D Leukemia
BRAF V600E Anaplastic Thyroid Cancer 1: Dabrafenib+Trametinib; 3B: Dabrafenib; 3B: Encorafenib+Cetuximab; 3B: Selumetinib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Encorafenib+Panitumumab; 3B: Trametinib; 3B: Vemurafenib; 3B: Vemurafenib+Cobimetinib; 3B: Encorafenib+Binimetinib;
BRAF V600K Anaplastic Thyroid Cancer 3B: Dabrafenib+Trametinib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Trametinib; 3B: Vemurafenib+Cobimetinib; 3B: Encorafenib+Binimetinib;
BRAF V600E Melanoma 1: Dabrafenib; 1: Dabrafenib+Trametinib; 1: Vemurafenib+Atezolizumab+Cobimetinib; 1: Trametinib; 1: Vemurafenib; 1: Vemurafenib+Cobimetinib; 1: Encorafenib+Binimetinib; 3B: Encorafenib+Cetuximab; 3B: Selumetinib; 3B: Encorafenib+Panitumumab;
BRAF V600K Melanoma 1: Dabrafenib+Trametinib; 1: Vemurafenib+Atezolizumab+Cobimetinib; 1: Trametinib; 1: Vemurafenib+Cobimetinib; 1: Encorafenib+Binimetinib;
BRAF V600G Melanoma 1: Vemurafenib+Atezolizumab+Cobimetinib; 2: Encorafenib+Binimetinib; 2: Dabrafenib+Trametinib; 2: Vemurafenib+Cobimetinib;
BRAF V600E NSCLC 1: Dabrafenib+Trametinib; 1: Encorafenib+Binimetinib; 3B: Dabrafenib; 3B: Encorafenib+Cetuximab; 3B: Selumetinib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Encorafenib+Panitumumab; 3B: Trametinib; 3B: Vemurafenib; 3B: Vemurafenib+Cobimetinib;
BRAF V600K NSCLC 3B: Dabrafenib+Trametinib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Trametinib; 3B: Vemurafenib+Cobimetinib; 3B: Encorafenib+Binimetinib;
BRAF V600G NSCLC 3B: Encorafenib+Binimetinib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Dabrafenib+Trametinib; 3B: Vemurafenib+Cobimetinib;
BRAF V600K NSCLC 3B: Dabrafenib+Trametinib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Trametinib; 3B: Vemurafenib+Cobimetinib; 3B: Encorafenib+Binimetinib;
BRAF V600E Colorectal Cancer 1: Encorafenib+Cetuximab; 2: Encorafenib+Panitumumab; 3B: Dabrafenib; 3B: Dabrafenib+Trametinib; 3B: Selumetinib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Trametinib; 3B: Vemurafenib; 3B: Vemurafenib+Cobimetinib; 3B: Encorafenib+Binimetinib;
BRAF V600K Colorectal Cancer 3B: Dabrafenib+Trametinib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Trametinib; 3B: Vemurafenib+Cobimetinib; 3B: Encorafenib+Binimetinib;
BRAF V600E Anaplastic Thyroid Cancer 1: Dabrafenib+Trametinib; 3B: Dabrafenib; 3B: Encorafenib+Cetuximab; 3B: Selumetinib; 3B: Tovorafenib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Encorafenib+Panitumumab; 3B: Trametinib; 3B: Vemurafenib; 3B: Vemurafenib+Cobimetinib; 3B: Encorafenib+Binimetinib;
BRAF V600K Anaplastic Thyroid Cancer 3B: Dabrafenib+Trametinib; 3B: Tovorafenib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Trametinib; 3B: Vemurafenib+Cobimetinib; 3B: Encorafenib+Binimetinib;
BRAF V600E Melanoma 1: Dabrafenib; 1: Dabrafenib+Trametinib; 1: Vemurafenib+Atezolizumab+Cobimetinib; 1: Trametinib; 1: Vemurafenib; 1: Vemurafenib+Cobimetinib; 1: Encorafenib+Binimetinib; 3B: Encorafenib+Cetuximab; 3B: Selumetinib; 3B: Tovorafenib; 3B: Encorafenib+Panitumumab;
BRAF V600K Melanoma 1: Dabrafenib+Trametinib; 1: Vemurafenib+Atezolizumab+Cobimetinib; 1: Trametinib; 1: Vemurafenib+Cobimetinib; 1: Encorafenib+Binimetinib; 3B: Tovorafenib;
BRAF V600G Melanoma 1: Vemurafenib+Atezolizumab+Cobimetinib; 2: Encorafenib+Binimetinib; 2: Dabrafenib+Trametinib; 2: Vemurafenib+Cobimetinib; 3B: Tovorafenib;
BRAF V600E NSCLC 1: Dabrafenib+Trametinib; 1: Encorafenib+Binimetinib; 3B: Dabrafenib; 3B: Encorafenib+Cetuximab; 3B: Selumetinib; 3B: Tovorafenib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Encorafenib+Panitumumab; 3B: Trametinib; 3B: Vemurafenib; 3B: Vemurafenib+Cobimetinib;
BRAF V600K NSCLC 3B: Dabrafenib+Trametinib; 3B: Tovorafenib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Trametinib; 3B: Vemurafenib+Cobimetinib; 3B: Encorafenib+Binimetinib;
BRAF V600G NSCLC 3B: Encorafenib+Binimetinib; 3B: Tovorafenib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Dabrafenib+Trametinib; 3B: Vemurafenib+Cobimetinib;
BRAF V600E Colorectal Cancer 1: Encorafenib+Cetuximab; 2: Encorafenib+Panitumumab; 3B: Dabrafenib; 3B: Dabrafenib+Trametinib; 3B: Selumetinib; 3B: Tovorafenib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Trametinib; 3B: Vemurafenib; 3B: Vemurafenib+Cobimetinib; 3B: Encorafenib+Binimetinib;
BRAF V600K Colorectal Cancer 3B: Dabrafenib+Trametinib; 3B: Tovorafenib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Trametinib; 3B: Vemurafenib+Cobimetinib; 3B: Encorafenib+Binimetinib;
BRAF V600E HCL 2: Vemurafenib;
BRAF V600K Pilocytic Astrocytoma 3B: Dabrafenib+Trametinib; 3B: Trametinib; 3B: Vemurafenib+Cobimetinib; 3B: Encorafenib+Binimetinib;
BRAF V600E Pilocytic Astrocytoma 1: Dabrafenib+Trametinib; 2: Selumetinib; 2: Vemurafenib+Cobimetinib; 3B: Dabrafenib; 3B: Encorafenib+Cetuximab; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Encorafenib+Panitumumab; 3B: Trametinib; 3B: Vemurafenib; 3B: Encorafenib+Binimetinib;
BRAF V600E Pilocytic Astrocytoma 1: Dabrafenib+Trametinib; 2: Selumetinib; 2: Vemurafenib+Cobimetinib; 3B: Dabrafenib; 3B: Encorafenib+Cetuximab; 3B: Tovorafenib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Encorafenib+Panitumumab; 3B: Trametinib; 3B: Vemurafenib; 3B: Encorafenib+Binimetinib;
BRAF V600K HCL
AKT1 E17K Breast Cancer 1: Capivasertib+Fulvestrant; 3B: Capivasertib;
AKT1 E17K NSCLC 3B: Capivasertib; 3B: Capivasertib+Fulvestrant;
Expand Down Expand Up @@ -193,8 +192,8 @@ KRAS G12A Histiocytosis 3A: Cobimetinib; 3A: Trametinib;
IDH1 R132H AML 1: Ivosidenib; 1: Olutasidenib;
IDH1 R132G AML 1: Ivosidenib; 1: Olutasidenib;
FGFR2 FGFR2-BICC1 Fusion Cholangiocarcinoma 1: Pemigatinib; 1: Futibatinib; 3A: RLY-4008; 4: Erdafitinib; 4: AZD4547;
ERBB2 Amplification Breast Cancer 1: Trastuzumab; 1: Trastuzumab+Chemotherapy; 1: Ado-Trastuzumab Emtansine; 1: Lapatinib+Capecitabine; 1: Lapatinib+Letrozole; 1: Trastuzumab+Pertuzumab+Chemotherapy; 1: Neratinib; 1: Neratinib+Capecitabine; 1: Trastuzumab+Tucatinib+Capecitabine; 1: Trastuzumab Deruxtecan; 1: Margetuximab+Chemotherapy; 3B: Trastuzumab+Carboplatin-Taxol Regimen; 3B: Trastuzumab+Pertuzumab; 3B: Lapatinib+Trastuzumab; 3B: Pembrolizumab+Trastuzumab+Chemotherapy; 3B: Tucatinib+Trastuzumab;
ERBB2 Amplification Colorectal Cancer 1: Tucatinib+Trastuzumab; 2: Trastuzumab+Pertuzumab; 2: Lapatinib+Trastuzumab; 2: Trastuzumab Deruxtecan; 3B: Trastuzumab; 3B: Trastuzumab+Carboplatin-Taxol Regimen; 3B: Trastuzumab+Chemotherapy; 3B: Ado-Trastuzumab Emtansine; 3B: Pembrolizumab+Trastuzumab+Chemotherapy; 3B: Lapatinib+Capecitabine; 3B: Lapatinib+Letrozole; 3B: Trastuzumab+Tucatinib+Capecitabine; 3B: Margetuximab+Chemotherapy;
ERBB2 Amplification Breast Cancer 1: Trastuzumab; 1: Trastuzumab+Chemotherapy; 1: Ado-Trastuzumab Emtansine; 1: Lapatinib+Capecitabine; 1: Lapatinib+Letrozole; 1: Trastuzumab+Pertuzumab+Chemotherapy; 1: Neratinib; 1: Neratinib+Capecitabine; 1: Trastuzumab+Tucatinib+Capecitabine; 1: Trastuzumab Deruxtecan; 1: Margetuximab+Chemotherapy; 3B: Trastuzumab+Carboplatin-Taxol Regimen; 3B: Trastuzumab+Pertuzumab; 3B: Lapatinib+Trastuzumab; 3B: Trastuzumab+Docetaxel; 3B: Pembrolizumab+Trastuzumab+Chemotherapy; 3B: Tucatinib+Trastuzumab;
ERBB2 Amplification Colorectal Cancer 1: Tucatinib+Trastuzumab; 2: Trastuzumab+Pertuzumab; 2: Lapatinib+Trastuzumab; 2: Trastuzumab Deruxtecan; 3B: Trastuzumab; 3B: Trastuzumab+Carboplatin-Taxol Regimen; 3B: Trastuzumab+Chemotherapy; 3B: Trastuzumab+Docetaxel; 3B: Ado-Trastuzumab Emtansine; 3B: Pembrolizumab+Trastuzumab+Chemotherapy; 3B: Lapatinib+Capecitabine; 3B: Lapatinib+Letrozole; 3B: Trastuzumab+Pertuzumab+Chemotherapy; 3B: Neratinib; 3B: Neratinib+Capecitabine; 3B: Trastuzumab+Tucatinib+Capecitabine; 3B: Margetuximab+Chemotherapy;
RET KIF5B-RET Fusion NSCLC 1: Selpercatinib; 1: Pralsetinib; 2: Cabozantinib; 3A: Vandetanib;
RET KIF5B-RET Fusion Bladder Cancer 1: Selpercatinib; 3B: Cabozantinib; 3B: Vandetanib; 3B: Pralsetinib;
MET Amplification Non-Small Cell Lung Cancer 2: Crizotinib; 2: Capmatinib; 2: Tepotinib; 3A: Telisotuzumab Vedotin; R2: Erlotinib; R2: Gefitinib; R2: Osimertinib;
Expand Down
Loading

0 comments on commit 99cb699

Please sign in to comment.